|
T9407 |
Rasarfin
|
|
Others
,
Ras
|
|
Rasarfin inhibits Ras and ARF6. |
|
T41256 |
SP-96
|
|
Aurora Kinase
|
|
SP-96 is a highly effective and selective inhibitor of Aurora B with an IC50 of 0.316 nM. SP-96 shows selective growth inhibition in NCI60 screening, including MDA-MD-468 (GI50=107 nM). SP-96 can be used in triple negati... |
|
T9468 |
FR054
|
|
Others
|
|
FR054 is an inhibitor of the Hexosamine Biosynthetic Pathway (HBP) enzyme PGM3, with a remarkable anti-breast cancer effect. FR054 induces in different breast cancer cells a dramatic decrease in cell proliferation and su... |
|
T13780 |
MS1943
|
|
Apoptosis
,
Histone Methyltransferase
|
|
MS1943 is a orally bioavailable EZH2 selective degrader(IC50 of 120 nM). |
|
T13044 |
Mevociclib
|
SY-1365 |
CDK
|
|
Mevociclib (SY-1365) is a highly selective covalent inhibitor of CDK7. SY-1365 possesses therapeutic potential in both hematological and solid tumors. |
|
T6797 |
Telaglenastat
|
CB 839,CB839,CB-839 |
transporter
,
Glutaminase
,
Autophagy
|
|
Telaglenastat (CB 839) (IC50 of 24 nM), an effective, specific, and oral inhibitor, which is bioavailable glutaminase, for recombinant human GAC. |
|
T19664 |
ON1231320
|
GBO-006 |
Apoptosis
,
PLK
|
|
ON1231320 (GBO-006) is a Polo-like kinase 2 (PLK2) inhibitor. |
|
T2655 |
CEP-37440
|
CEP37440 |
FAK
,
ALK
|
|
CEP-37440 is an effective and specific Dual FAK/ALK inhibitor with IC50s of 120 nM(ALK cellular in 75% human plasma) and 2.3 nM (FAK). |
|
T9320 |
YK-3-237
|
B-[2-Methoxy-5-[(1E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propen-1-yl]phenyl]boronic acid |
Sirtuin
|
|
YK-3-237 (B-[2-Methoxy-5-[(1E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propen-1-yl]phenyl]boronic acid) reduces acetylation of mtp53 and exhibits anti-proliferative effects toward triple-negative breast cancer (TNBC) cells ca... |
|
T8808L |
LYN-1604 dihydrochloride
|
LYN-1604 2HCl（2216753-86-3 free base) |
Apoptosis
,
Autophagy
|
|
LYN-1604 is a novel ULK1 activator.It inducing cell death involved in ATF3, RAD21, and caspase3, accompanied by autophagy and apoptosis. |
|
T4123 |
LYN-1604
|
LYN1604 |
Apoptosis
,
Autophagy
|
|
LYN-1604 is a novel activator of ULK1, inducing cell death involved in ATF3, RAD21, and caspase3, accompanied by autophagy and apoptosis. |
|
T35528 |
TD52
|
|
Apoptosis
,
Phosphatase
,
Akt
|
|
TD52 is an orally active inhibitor of cancerous inhibitor of PP2A (CIP2A). TD52 is an Erlotinib derivative and indirectly reduced CIP2A by disturbing Elk1 binding to the CIP2A promoter. |
|
T70353 |
JG-231
|
|
HSP
|
|
JG-231 is a JG-98 analog with anticancer activity.JG-231 inhibits the MDA-MB-231 xenograft tumor model of triple-negative breast cancer (TNBC).JG-231 inhibits the interaction of Hsp70-BAG3.JG-231 inhibits the MDA-MB-231 ... |
|
T6224 |
Iniparib
|
NSC-746045,IND-71677,BSI-201 |
PARP
,
Influenza Virus
|
|
Iniparib (BSI-201) (BSI-201) , a PARP1 inhibitor, exhibits potency in triple-negative breast Y (TNBC). |
|
T8569 |
DMH-25
|
|
mTOR
|
|
DMH25 is a novel covalent and potent inhibitor of mTOR and shows in vivo antitumor activity against triple-negative breast cancer cells. |
|
T9583 |
HJ-PI01
|
N-Acetylphenoxazine,10-acetylphenoxazine |
Pim
|
|
HJ-PI01 (HJ-PI01) is a Pim-2 inhibitor. HJ-PI01 (HJ-PI01) induces apoptosis and autophagic cell death in triple-negative human breast cancer. |
|
T7296 |
THZ2
|
CDK7-IN-1 |
CDK
|
|
THZ2 (CDK7-IN-1), an analog of THZ1, is a potent and selective CDK7 inhibitor(IC50:13.9 nM),with the potential to treat Triple-negative breast cancer (TNBC). |
|
T74178 |
Glembatumumab vedotin
|
CR011-vcMMAE,CR 011 ADC,CDX-011 |
Microtubule Associated
|
|
Glembatumumab vedotin (CDX-011) is an antibody-activated small molecule coupling, Glembatumumab vedotin has potent anticancer effects and can be used in the study of triple negative breast cancer (TNBC). |
|
T77759 |
GPX4-IN-6
|
|
GPX
|
|
GPX4-IN-6 is a small molecule covalent GPX4 inhibitor (IC50: 0.12 μM) with antitumour activity.GPX4-IN-6 induces iron death and is used for the treatment= and prevention of triple negative breast cancer (TNBC). |
|
T72528 |
NSC243928 mesylate
|
|
HuR
|
|
NSC243928 mesylate binds to human lymphocyte antigen 6 (LY6), a cell growth inhibitor with anticancer activity, and induces cell death in triple-negative breast cancer cells in a LY6K-dependent manner. |
|
T14685 |
BMS-986158
|
|
Epigenetic Reader Domain
|
|
BMS-986158 is a highly effective BET inhibitor, demonstrating IC50 values of 6.6 nM in NCI-H211 small cell lung cancer (SCLC) cells and 5 nM in MDA-MB231 triple negative breast cancer (TNBC) cells. |
|
T8325 |
SR-4835
|
|
Apoptosis
,
CDK
|
|
SR-4835 is a highly selective dual inhibitor of CDK12 and CDK13(CDK12: IC50=99 nM, Kd=98 nM; CDK13: Kd=4.9 nM), which disables triple-negative breast cancer (TNBC) cells |
|
T77755 |
GPX4-IN-5
|
|
GPX
|
|
GPX4-IN-5 is a small molecule covalent GPX4 inhibitor (IC50: 0.12 μM) with antitumour activity.GPX4-IN-5 induces iron death and can be used for the prevention and treatment of triple-negative breast cancer (TNBC). |
|
T17206 |
UPGL00004
|
|
Others
,
Glutaminase
|
|
UPGL00004 is a potent glutaminase C (GAC) inhibitor with an IC50 of 29 nM. Kd of UPGL00004 for GAC was 27 nM. UPGL00004 has a strong inhibitory effect on the proliferation of highly aggressive triple negative breast canc... |
|
T35528L |
TD52 dihydrochloride
|
TD52 dihydrochloride(1798328-24-1 Free base),TD52 2HCl |
Others
|
|
TD52 dihydrochloride (TD52 2HCl), a derivative of Erlotinib, is a potent and orally active inhibitor of protein phosphatase 2A (CIP2A). It exhibits strong anti-cancer properties by regulating the CIP2A/PP2A/p-Akt signali... |
|
T62077 |
VT103
|
VT-103,VT 103 |
YAP
|
|
VT103 is an orally active and selective inhibitor of TEAD1 protein palmitoylation and is an analog of VT101. VT103 has potential antitumor activity by inhibiting YAP/TAZ-TEAD-promoted gene transcriptionment, blocking TEA... |
|
T11600 |
IBR2
|
Isoquinoline |
DNA/RNA Synthesis
|
|
IBR2 (Isoquinoline) is a potent and specific RAD51 inhibitor known for its ability to suppress RAD51-mediated DNA double-strand break repair. By interfering with RAD51 multimerization, accelerating proteasome-mediated RA... |
|
T40182 |
Ascochlorin A
|
Acremochlorin A |
|
|
Ascochlorin A, a compound with a dissociation constant (K D) of 3.29 μM, serves as a novel and potent human dihydroorotate dehydrogenase (hDHODH) inhibitor aimed at treating triple-negative breast cancer. |
|
T39992 |
FGFR1 inhibitor-2
|
FGFR1 inhibitor-2 |
|
|
FGFR1 inhibitor-2 (with an IC50 of 4.55 μM in MDA-MB-231 cells) is a potent inhibitor of FGFR1. It is specifically useful for studying metastatic triple-negative breast cancer. |
|
T39687 |
LYN-1604 hydrochloride
|
|
|
|
LYN-1604 hydrochloride, a powerful activator of UNC-51-like kinase 1 (ULK1) with an EC50 value of 18.94 nM, has significant implications in the study of triple-negative breast cancer (TNBC). |
|
T40310 |
PARP/EZH2-IN-1
|
PARP/EZH2-IN-1 |
|
|
PARP/EZH2-IN-1 is a novel compound that functions as a dual inhibitor for both PARP (IC50 6.87 nM) and EZH2 (IC50 36.51 nM), showing promising potential for the treatment of triple-negative breast cancer with wild-type B... |
|
T2092L |
Amitifadine free base
|
DOV 21947,DOV-21947,DOV21,947,DOV21947,DOV 21,947,DOV-21,947 |
|
|
Amitifadine(DOV-21947, EB-1010) is an inhibitor of the so-called triple reuptake or serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) and is an antidepressant drug candidate. Amitifadine reduces binge drinking... |
|
T13889 |
SLLN-15
|
|
Others
|
|
SLLN-15 is an oral active, selective and potent enhancer of autophagy. SLLN-15 activates cytostatic macroautophagy/autophagy in triple-negative breast cancer (TNBC) [1]. |
|
T72638 |
INOS inhibitor-10
|
|
NO Synthase
|
|
iNOS Inhibitor-10, with an IC50 of 65 nM, exhibits antiproliferative effects on triple-negative breast cancer cells [1]. |
|
T40891 |
ADTL-SA1215
|
ADTL-SA1215 |
|
|
ADTL-SA1215 is a novel, highly selective small-molecule compound that acts as a specific activator of SIRT3, a protein known to play a crucial role in modulating autophagy. This compound holds great potential in the trea... |
|
T80216 |
DOTA-CXCR4-L
|
|
CXCR
|
|
DOTA-CXCR4-L, a peptide targeting the CXCR4 receptor, is utilized in cancer research, notably in the contexts of glioblastoma and triple-negative breast cancer [1]. |
|
T74219 |
Maximiscin
|
|
|
|
Maximiscin, a metabolite derived from fungi, causes DNA damage and exhibits selective cytotoxic activity towards a specific subtype of triple-negative breast cancer. |
|
T73995 |
EGFR/CSC-IN-1
|
|
EGFR
|
|
EGFR/CSC-IN-1 is a dual inhibitor targeting both the epidermal growth factor receptor (EGFR [IC50 10.52 nM]) and cancer stem cells (CSC), with potential applications in triple-negative breast cancer research. |
|
T72328 |
Cyclopropenone probe 1
|
|
|
|
Cyclopropenone probe 1 can specifically and efficiently modify a triple-negative breast cancer driver, glutathione S-transferase pi-1 (GSTP1) , by covalently binding at the catalytic active site. |
|
T60749 |
Autophagy-IN-2
|
|
|
|
Autophagy-IN-2 (Compound 7h) is an inhibitor of autophagic flux which induces cancer cell apoptosis and can be used for the research of triple-negative breast cancer [1]. |
|
T69437 |
NDJ18
|
|
|
|
NDJ18 is a potent and selective SIRT2 inhibitor which validated the in silico protocol and opened up the possibility for generalization and broadening of its application. The anticancer effects of the most potent compoun... |
|
T74802 |
FAK-IN-9
|
|
|
|
FAK-IN-9 (Compound 8f) is a potent, orally active inhibitor of FAK, demonstrating an IC50 value of 27.44 nM. This compound effectively induces apoptosis in triple-negative breast cancer (TNBC) cells [1]. |
|
T64053 |
Bcl-2-IN-8
|
|
|
|
Bcl-2-IN-8 is a potent anti-cancer agent. bcl-2-IN-8 exhibits anti-proliferative effects on both drug-sensitive and drug-resistant cancer cells. bcl-2-IN-8 inhibits cell migration in a dose-dependent manner. bcl-2-IN-8 b... |
|
T74675 |
MS8815
|
|
|
|
MS8815, a selective proteolysis targeting chimera (PROTAC) degrader of enhancer of zeste homolog 2 (EZH2), exhibits inhibitory activity with an IC50 value of 8.6 nM. It is utilized in the research of triple-negative brea... |
|
T79410 |
Anti-TNBC agent-3
|
|
|
|
Anti-TNBC agent-3 (compound 3g) is a compound that induces apoptosis and possesses anti-cancer cell proliferation properties. It effectively inhibits tumor growth and metastasis in xenograft models of triple-negative bre... |
|
T79604 |
SHR5428
|
|
CDK
|
|
SHR5428 is an orally active, selective, noncovalent inhibitor of CDK7, displaying potent enzymatic inhibition (IC50 = 2.3 nM) and effectively suppressing cellular activity in triple-negative breast cancer MDA-MB-468 cell... |
|
T39815 |
Anti-TNBC agent-1
|
|
|
|
anti-TNBC agent-1 is a highly effective compound specifically designed to target and combat triple-negative breast cancer (TNBC). It demonstrates remarkable potency against various breast cancer cell types, with IC50 val... |
|
T62540 |
PARP1/BRD4-IN-2
|
|
|
|
PARP1/BRD4-IN-2 is a potent and selective inhibitor of PARP1 (IC50: 197 nM) and BRD4 (IC50: 238 nM).PARP1/BRD4-IN-2 inhibits DNA damage repair, blocks the G0/G1 cell cycle transition, and induces apoptosis.PARP1/BRD4-IN-... |
|
T61582 |
Anticancer agent 57
|
|
|
|
Anticancer agent 57 (compound 14) demonstrates potent inhibition of MDA-MB-231, MDA-MB-468, and MCF-7 cell lines, with IC 50 values ranging from 6.43 to 8.00 μM. Additionally, this agent induces cell cycle arrest and pro... |
|
T73501 |
MC0704
|
|
|
|
MC0704 is a STAT3 inhibitor that demonstrates antitumor activity specifically in mouse breast cancer models, possessing an IC50 value of 2.13 μM. It is effective in inducing cell apoptosis and cell cycle arrest, making i... |
